This article has been updated to correct the operating expenses for the third quarter of 2009.
As it is preparing for its initial public offering, Complete Genomics this week reported $4.2 million in revenue for the third quarter, along with a net loss of $20.5 million.
The company had no revenue during the third quarter of 2009, and a $9.25 million net loss.
As previously stated, Complete Genomics had $9 million worth of backlog orders as of Sept. 30, for which it expects to bill customers within the next 12 months.
The company had operating expenses of $14.9 million during the quarter, up from $8.6 million during the year-ago quarter. As of Sept. 30, it had $10.5 million in cash and cash equivalents.
Last month, Complete Genomics raised its maximum aggregate offering price for its planned IPO to $96.6 million, from an earlier target of $86.25 million (IS 10/26/2010).